Definiens to Host International Symposium for Tissue Phenomics®
12 April 2017 - 8:00AM
Business Wire
Summit to Present Advancements in Tissue Phenomics,
Immuno-profiling, Immuno-Oncology and Big Data
Definiens, the pioneer in Tissue Phenomics solutions for
diagnostics and clinical development, today announced that
additional seating has been added to the company’s upcoming annual
conference, The International Symposium for Tissue Phenomics,
taking place April 25-26, 2017 in Amsterdam, Netherlands. Tissue
Phenomics, the use of unique tissue signatures correlated to
genetic and patient outcome data to develop precise and powerful
tissue-based diagnostics, continues to be a decisive tool in
oncology personalized medicine.
Definiens’ Symposium focuses on dynamic immunotherapy
advancements and the powerful convergence of computational science,
bioinformatics and digital pathology through the use of big data to
support the promising space of precision medicine.
This year’s event will feature presentations and discussions by
leading, distinguished researchers and speakers, including:
- Corinne Berclaz, Imaging Specialist,
Roche
- Simone Bianco, IBM Research & Rock
Star Employee
- Ken Bloom, Head of Oncology &
Immunotherapy, Human Longevity
- Sebastian Brandner, Professor of
Neuropathy, Head of Division, University College London Institute
of Neurology
- Joachim Deeg, Professor of Medicine,
Fred Hutch Cancer Research Center
- Bernard Fox, Chief, Molecular &
Tumor Immunology, Providence Cancer Center
- Heike Grabsch, Professor of GI
Pathology, University Medical Center of Maastricht
- James Gulley, Director of the Medical
Oncology Service & Head, National Cancer Center NIH
- David Harrison, Symposium Co-Chair
School of Medicine, University of St. Andrews
- Babis Hatzikirou, Group Leader,
Helmholtz Centre for Infection Research
- Cyrus Hedvat, Director of Pathology,
BMS
- Ron Herbst, VP Oncology, MedImmune
- Mischa Houtkamp, Senior Scientist,
Genmab
- Ryan Hutchinson, Immuno-oncology and
Digital Pathology Fellow, Centre for Translational Pathology, The
University of Melbourne
- Dirk Jäger, Professor of Medical
Oncology, NCT Heidelberg
- Bahija Jallal, EVP AstraZeneca and Head
of MedImmune
- Hartmut Juhl, Founder & CEO,
Indivumed
- Arne Ostman, Professor of Molecular
Oncology, Pathology Karolinska Institute
- Lawrence Weiss, Medical Director,
NeoGenomics
The annual Symposium addresses the most critical issues in
oncology. "The question is no longer whether digital pathology has
a role in clinical practice, but rather how revolutionary that role
should be," says David Harrison, Symposium Co-Chair School of
Medicine, North Haugh University of St. Andrews.
Ralf Huss, CMO at Definiens shares that, “Tissue Phenomics is a
core competence for advanced image analysis solutions &
multi-dimensional applications. The use of Quantitative Pathology
Biomarker Analysis is becoming more prevalent and sophisticated in
its use in Clinical Trials and Diagnostics for
Immuno-Oncology.”
From generic solutions to complex multidimensional applications
Tissue Phenomics has become the core technology for advanced image
analysis and data mining along the entire value chain. The use of
quantitative and informative pathology with added spatial
information and computational excellence provides an unprecedented
opportunity for the identification of novel biomarker solutions in
clinical development and precision diagnostics for
immuno-oncology.
The symposium takes place from April 25-26, 2017 at the NH Grand
Hotel Krasnapolsky in Amsterdam. To register online please visit
www.tissuephenomics.com
About Definiens
Definiens improves patient lives by unlocking the tissue
phenome. In oncology, therapeutic strategies have shifted from a
direct assault on cancer cells to recruiting the immune system for
that purpose. Definiens’ mission is to accelerate breakthroughs for
this approach by helping scientists leverage Tissue Phenomics to
deepen understanding of disease biology and immune system
mechanisms, to bring multi-omics data into a cancer-relevant
context, and to facilitate the translation of new insights into
novel therapies and treatment strategies. Definiens vision is to
create unique patient profiles for an individualized standard of
care, where patients experience fewer side effects and live
longer.
Definiens' Tissue Phenomics approach was awarded the 2013 Frost
and Sullivan Company of the Year Award for Global Tissue
Diagnostics and Pathology Imaging. For more information, please
visit: www.definiens.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170411006337/en/
DefiniensLina WillisGlobal Marketing and Scientific
Conferences Managerlwillis@definiens.com